Blog Layout

The National Cancer Advisory Board (NCAB) ad hoc Informatics Working Group (IWG)

Established in mid-2011 by the NCAB, the IWG is charged with providing strategic guidance and direction on NCI informatics investments that support the Institute’s scientific goals. The IWG provides a venue for identifying high-priority biomedical informatics needs, harmonizing ongoing and proposed informatics projects across NCI programs, both intramural and extramural, and reducing redundancies wherever possible. The IWG will explore informatics efforts, potential initiatives, and business models that are in accord with the changes that have occurred in the conduct of cancer research, the practice of oncology, and research administration.


The NCIP Informatics Council


Established in September 2012, the Informatics Council will ensure strategic alignment across NCI award and training programs in biomedical informatics and provide guidance so that NCI CBIIT and its principal program initiative, the NCIP, can prioritize projects and activities. The Council will also serve as a venue for CBIIT and NCIP Working Groups to bring forward strategic recommendations based on interactions with the wider biomedical informatics community, which will further the Institute’s bioinformatics goals in support of scientific research.


NCIP Working Groups (WGs)


CBIIT will convene WGs in focused subject areas. The goals of these groups will be to

  • facilitate extramural input into NCIP priorities,
  • provide subject-matter expertise in the specific areas around which the groups are convened, and
  • support the definition of informatics requirements and priorities in specific domains.

These groups may be established and dissolved over time, as needs dictate, based on the recommendations of the Council. WGs will have representation from one or more appropriate NCI DOCs (Divisions, Offices, and Centers), as well as from key extramural scientific and informatics programs in the cancer research community.


The first three WGs established by the Council are in the areas of High-throughput Molecular Data, Imaging Informatics, and Next-Generation Semantic Infrastructure.


The High-throughput Molecular Data WG will examine NCI program needs and priorities for the management, analysis, aggregation, and integration of data generated by high-throughput technologies; both basic research and clinical applications of these data will be considered. The initial focus will be on informatics initiatives for next-generation sequencing data, given the rapid advances and significant needs pertaining to these rapidly growing data collections. The group’s long-term objectives include

  • Lowering barriers to accessing and using data and high-throughput analytical tools
  • Encouraging a philosophy of sharing tools, data sets, and expertise
  • Providing essential resources for NCI research
  • Fostering partnerships to sustain collaborations in the community


The Imaging Informatics WG has the goal of examining NCI program needs and priorities for imaging informatics solutions across the cancer research continuum, from basic and preclinical studies (including small-animal imaging) through translational and clinical research. This continuum also requires standardizing and validating research algorithms and technologies for analyzing enormous amounts of imaging data and metadata in ways needed to satisfy the regulatory requirements set by the U.S. Food and Drug Administration (FDA). The group’s long-term objectives include

  • Lowering barriers to performing imaging research with new modalities and analytical tools
  • Encouraging a philosophy of sharing tools, data sets, and expertise
  • Providing essential resources for NCI (and eventually the larger community)
  • Fostering partnerships to sustain collaborations in the community
  • Building a sustainable, collaborative community within NCI and subsequently the larger research community


The Next-Generation Semantic Infrastructure WG will identify and prioritize high-level needs as the semantic infrastructure is implemented. As its components are developed, the group will validate the infrastructure through application to a number of selected biomedical research projects. The group will identify projects with specific, unmet needs that can be addressed by the semantic infrastructure, and validate that it is effective in meeting those needs. Where needs are not met by existing semantic infrastructure, the working group will assess the generalizability of the need across multiple projects, and determine whether creating new or evolving existing infrastructure to meet these needs is warranted. The group’s long-term objectives include

  • Identifying needs in the NCI research community that the semantic infrastructure can address, with a focus on enabling interoperability and data-sharing that expedite and facilitate projects within and across scientific domains
  • Identifying scientific projects where project teams can apply the semantic infrastructure to validate its practicality and applicability
  • Lowering barriers to the access and use of data through the provision of semantic infrastructure tools and methodologies
  • Encouraging a philosophy of sharing tools, data sets, and expertise
  • Providing essential resources to NCI (and eventually the larger community)
  • Fostering partnerships to sustain collaborations in the community


Share this Article with others

08 Mar, 2024
The aims of our case-control study were (1) to develop an automated 3-dimensional (3D) Convolutional Neural Network (CNN) for detection of pancreatic ductal adenocarcinoma (PDA) on diagnostic computed tomography scans (CTs), (2) evaluate its generalizability on multi-institutional public data sets, (3) its utility as a potential screening tool using a simulated cohort with high pretest probability, and (4) its ability to detect visually occult preinvasive cancer on prediagnostic CTs.
08 Mar, 2024
Cancer Mutations Converge on a Collection of Protein Assemblies to Predict Resistance to Replication Stress
08 Mar, 2024
International cancer registries make real-world genomic and clinical data available, but their joint analysis remains a challenge. AACR Project GENIE, an international cancer registry collecting data from 19 cancer centers, makes data from >130,000 patients publicly available through the cBioPortal for Cancer Genomics (https://genie.cbioportal.org). For 25,000 patients, additional real-world longitudinal clinical data, including treatment and outcome data, are being collected by the AACR Project GENIE Biopharma Collaborative using the PRISSMM data curation model. Several thousand of these cases are now also available in cBioPortal. We have significantly enhanced the functionalities of cBioPortal to support the visualization and analysis of this rich clinico-genomic linked dataset, as well as datasets generated by other centers and consortia. Examples of these enhancements include (i) visualization of the longitudinal clinical and genomic data at the patient level, including timelines for diagnoses, treatments, and outcomes; (ii) the ability to select samples based on treatment status, facilitating a comparison of molecular and clinical attributes between samples before and after a specific treatment; and (iii) survival analysis estimates based on individual treatment regimens received. Together, these features provide cBioPortal users with a toolkit to interactively investigate complex clinico-genomic data to generate hypotheses and make discoveries about the impact of specific genomic variants on prognosis and therapeutic sensitivities in cancer.
08 Mar, 2024
The majority of disease-associated variants identified through genome-wide association studies are located outside of protein-coding regions. Prioritizing candidate regulatory variants and gene targets to identify potential biological mechanisms for further functional experiments can be challenging. To address this challenge, we developed FORGEdb, a standalone and web-based tool that integrates multiple datasets, delivering information on associated regulatory elements, transcription factor binding sites, and target genes for over 37 million variants. FORGEdb scores provide researchers with a quantitative assessment of the relative importance of each variant for targeted functional experiments.
By Bo Zhang 08 Mar, 2024
Cancer is a leading cause of morbidity and mortality worldwide. While progress has been made in the diagnosis, prognosis, and treatment of cancer patients, individualized and data-driven care remains a challenge. Artificial intelligence (AI), which is used to predict and automate many cancers, has emerged as a promising option for improving healthcare accuracy and patient outcomes. AI applications in oncology include risk assessment, early diagnosis, patient prognosis estimation, and treatment selection based on deep knowledge. Machine learning (ML), a subset of AI that enables computers to learn from training data, has been highly effective at predicting various types of cancer, including breast, brain, lung, liver, and prostate cancer. In fact, AI and ML have demonstrated greater accuracy in predicting cancer than clinicians. These technologies also have the potential to improve the diagnosis, prognosis, and quality of life of patients with various illnesses, not just cancer. Therefore, it is important to improve current AI and ML technologies and to develop new programs to benefit patients. This article examines the use of AI and ML algorithms in cancer prediction, including their current applications, limitations, and future prospects. Lead Author: Bo Zhang
By Claudio Luchini 08 Mar, 2024
Artificial intelligence (AI) is concretely reshaping the landscape and horizons of oncology, opening new important opportunities for improving the management of cancer patients. Analysing the AI-based devices that have already obtained the official approval by the Federal Drug Administration (FDA), here we show that cancer diagnostics is the oncology-related area in which AI is already entered with the largest impact into clinical practice. Furthermore, breast, lung and prostate cancers represent the specific cancer types that now are experiencing more advantages from AI-based devices. The future perspectives of AI in oncology are discussed: the creation of multidisciplinary platforms, the comprehension of the importance of all neoplasms, including rare tumours and the continuous support for guaranteeing its growth represent in this time the most important challenges for finalising the ‘AI-revolution’ in oncology. First Author: Claudio Luchini,
By Panayiotis Petousis, PhD 08 Mar, 2024
In the United States, end-stage kidney disease (ESKD) is responsible for high mortality and significant healthcare costs, with the number of cases sharply increasing in the past 2 decades. In this study, we aimed to reduce these impacts by developing an ESKD model for predicting its occurrence in a 2-year period.  Lead Author: Panayiotis Petousis, PhD
By Evan D. Muse 08 Mar, 2024
Transforming the cardiometabolic disease landscape: Multimodal AI-powered approaches in prevention and management Lead Author: Evan D. Muse
By Danielle S. Bitterman, MD 08 Mar, 2024
Current status and future applications of LLMs for cancer symptom management and call for cross-disciplinary collaboration that centers the needs of patients and caregivers L ead Author: Danielle S. Bitterman, MD
01 Mar, 2023
New computer systems aim to peer inside our heads—and to help us fix what they find there In the nineteen-sixties, Joseph Weizenbaum, a computer scientist at M.I.T., created a computer program called Eliza. It was designed to simulate Rogerian therapy, in which the patient directs the conversation and the therapist often repeats her language back to her: U ser : My boyfriend made me come here. E liza : Your boyfriend made you come here. U ser : He says I’m depressed much of the time. E liza : I am sorry to hear you are depressed. U ser : It’s true. I am unhappy. E liza : Do you think coming here will help you not to be unhappy? Weizenbaum made Eliza as satire. He doubted that computers could simulate meaningful human interaction. He was alarmed, therefore, when many people who tried the program found it both useful and captivating. His own secretary asked him to leave the room so that she could spend time alone with Eliza. Worse, doctors saw it as a potentially transformative tool. “Several hundred patients an hour could be handled by a computer system designed for this purpose,” three psychiatrists wrote in The Journal of Nervous and Mental Disease, in 1966. “The human therapist, involved in the design and operation of this system, would not be replaced, but would become a much more efficient man since his efforts would no longer be limited to the one-to-one patient-therapist ratio as now exists.” Weizenbaum became an outspoken critic of artificial intelligence. “But the genie was out of the bottle,” Brian Christian, who chronicled the episode in his book “The Most Human Human,” told me. A few years later, a Stanford psychiatrist named Kenneth Colby created Parry, a program that attempted to simulate the language of a person with paranoid schizophrenia, to train students before they cared for real patients. Psychiatrists given transcripts of therapy sessions often couldn’t tell the difference between Parry and humans; in this narrow sense, the chatbot passed the Turing test. In 1972, Parry and Eliza met up for a therapy session: P arry : Do you know anything about bookies? E liza : What makes you think I know anything about bookies? P arry : A bookie didn’t pay me off once. E liza : What does that suggest to you? P arry : I beat up the bookie who did not pay off, and I thought he might use his friends in the underworld to get even with me.  Over time, programmers developed Jabberwacky, Dr. Sbaitso, and alice (the Artificial Linguistic Internet Computer Entity). Exchanges with these chatbots were often engaging, sometimes comical, and occasionally nonsensical. But the idea that computers could serve as human confidants, expanding therapy’s reach beyond the limits of its overworked practitioners, persisted through the decades. In 2017, Alison Darcy, a clinical research psychologist at Stanford, founded Woebot, a company that provides automated mental-health support through a smartphone app. Its approach is based on cognitive behavioral therapy, or C.B.T.—a treatment that aims to change patterns in people’s thinking. The app uses a form of artificial intelligence called natural language processing to interpret what users say, guiding them through sequences of pre-written responses that spur them to consider how their minds could work differently. When Darcy was in graduate school, she treated dozens of hospitalized patients using C.B.T.; many experienced striking improvements but relapsed after they left the hospital. C.B.T. is “best done in small quantities over and over and over again,” she told me. In the analog world, that sort of consistent, ongoing care is hard to find: more than half of U.S. counties don’t have a single psychiatrist, and, last year, a survey conducted by the American Psychological Association found that sixty per cent of mental-health practitioners don’t have openings for new patients. “No therapist can be there with you all day, every day,” Darcy said. Although the company employs only about a hundred people, it has counseled nearly a million and a half, the majority of whom live in areas with a shortage of mental-health providers. Link to original article on The New Yorker
Share by: